Kyverna Therapeutics (KYTX) Income from Continuing Operations (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Income from Continuing Operations of 74163000.0 for Q1 2026, down 81.45% on a QoQ basis from 40872000.0 in Q4 2025, and down 62.83% year-over-year from 199529091.97 in Q1 2025.
Kyverna Therapeutics (KYTX) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 74163000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 62.83% year-over-year to 74163000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 212092000.0 (down 24.3% YoY) and the FY2025 annual result came in at 204554000.0, down 56.97% from the prior year.
- Income from Continuing Operations was 74163000.0 for Q1 2026 at Kyverna Therapeutics, down from 40872000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11661000.0 in Q1 2023 and bottomed at 74163000.0 in Q1 2026.
- A 4-year average of 36265615.38 and a median of 40872000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 203.32% — and 2025, when it fell 1.11%.
- Kyverna Therapeutics' Income from Continuing Operations stood at 19006000.0 in 2023, then plunged by 112.69% to 40424000.0 in 2024, then fell by 1.11% to 40872000.0 in 2025, then slumped by 81.45% to 74163000.0 in 2026.
- Business Quant data shows KYTX's Income from Continuing Operations at 74163000.0 in Q1 2026, 40872000.0 in Q4 2025, and 52850000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Kyverna Therapeutics | 440.57 Mn | 440.57 Mn | - | -74.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.16 Mn |
| Dec 31, 2025 | -40.87 Mn |
| Sep 30, 2025 | -52.85 Mn |
| Jun 30, 2025 | -44.21 Mn |
| Mar 31, 2025 | -45.55 Mn |
| Dec 31, 2024 | -40.42 Mn |
| Sep 30, 2024 | -43.29 Mn |
| Jun 30, 2024 | -41.37 Mn |
| Mar 31, 2024 | -28.42 Mn |
| Dec 31, 2023 | -19.01 Mn |
| Sep 30, 2023 | -16.00 Mn |
| Jun 30, 2023 | -13.64 Mn |
| Mar 31, 2023 | -11.66 Mn |